T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2

Clinical and Experimental Metastasis

Volumn 32, Issue 1, 2015, Pages 29-38

  Nicoletti, Roberta ^a,b   Lopez, Salvatore ^a,c   Bellone, Stefania ^a   Cocco, Emiliano ^a   Schwab, Carlton L ^a   Black, Jonathan D ^a   Centritto, Floriana ^a,b   Zhu, Liancheng ^a,d   Bonazzoli, Elena ^a   Buza, Natalia ^a   Hui, Pei ^a   Mezzanzanica, Delia ^b   Canevari, Silvana ^b   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Santin, Alessandro D ^a,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d Shengjing Hospital Affiliated to China Medial University   (China)

^e NONE   (United States)

Author keywords

Carcinosarcoma; HER2; T DM1; Trastuzumab; Trastuzumab emtansine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB EMTANSINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, MOUSE; MAYTANSINE; MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CARCINOSARCOMA; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRACTICE GUIDELINE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETICS; IMMUNOLOGY; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; OVARIAN NEOPLASMS; SCID MOUSE; TUMOR CELL LINE; UTERINE NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CARCINOSARCOMA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; IMMUNOCONJUGATES; M PHASE CELL CYCLE CHECKPOINTS; MAYTANSINE; MICE; MICE, SCID; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TRASTUZUMAB; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930044513     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-014-9688-8     Document Type: Article

References (33)

1. D’Angelo E, Prat J (2011) Pathology of mixed Müllerian tumours. Hum Pathol Best Pract Res Clin Obstet Gynaecol 25:705–718
2. Brooks SE, Zhan M, Cote T, Baquet CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 93:204–208
3. Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A (2011) Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 1:CD006812
4. Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT (2010) Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer 20:888–894
5. Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D’Hondt V, Piccart M, Awada A (2007) Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 17:316–324
6. del Carmen MG, Birrer M, Schorge JO (2012) Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol 125:271–277
7. Jonson AL, Bliss RL, Truskinovsky A, Judson P, Argenta P, Carson L, Dusenbery K, Downs LS Jr (2006) Clinical features and outcomes of uterine an ovarian carcinosarcoma. Gynecol Oncol 100:561–564
8. Cantrell LE, Van Le L (2009) Carcinosarcoma of the ovary: a review. Obstet Gynecol Surv 64:673–680
9. Inthasorn P, Beale P, Dairymple C, Carter J (2003) Malignant mixed müllerian tumour of the ovary: prognostic factor and response to adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol 43:61–64
10. McCluggage WG (2002) Uterine carcinosarcomas (malignant mixed Müllerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 12:687–690
11. McCluggage WG (2002) Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 55:321–325
12. Tebbutt N, Pedersen MW, Johns TG (2013) Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 13:663–673
13. Park JW, Neve RM, Szollosi J, Benz CC (2008) Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 8:392–401
14. Tai Wanyi, Mahato Rubi, Cheng Kun (2010) The role of HER2 in cancer therapy and targeted drug delivery. J Controll Releas 146:264–275
15. Yan M, Parker BA, Schwab R, Kurzrock R (2014) HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev 40:770–780
16. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005) Amplification of c-erbB-2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104:1391–1397
17. El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD (2010) In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 102:134–143
18. Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P (2007) Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol 105:138–144
19. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA (2006) EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 100:101–106
20. Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, Scarselli G, Taddei GL (2005) COX-2, c-KIT and HER2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol 96:159–167
21. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, Yamada T, Kikuchi Y, Honjo H, Matsubara O (2003) Different expression patterns of KIT, EGFR, and HER-2 (cerbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 94:986–991
22. Amant F, Vloeberghs V, Woestenborghs H, Debiec-Rychter M, Verbist L, Moerman P, Vergote I (2004) ERBB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol 95:583–587
23. Gabos Z, Sinha R, Hanson J, Chauhan N, Hugh J, Mackey JR, Abdulkarim B (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658–5663
24. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648
25. Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K (2013) Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin 29:405–414
26. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2- positive breast cancer with trastuzumab-DM1, an antibodycytotoxic drug conjugate. Cancer Res 68:9280–9290
27. Guzzo F, Bellone S, Buza N, Hui P, Carrara L, Varughese J, Cocco E, Betti M, Todeschini P, Gasparrini S, Schwartz PE, Rutherford TJ, Angioli R, Pecorelli S, Santin AD (2012) HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol 31:211–221
28. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
29. Barok M, Tannerb M, Köninki K, Isola J (2011) Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett 306:171–179
30. Cretella D, Saccani F, Quaini F, Frati C, Lagrasta C, Bonelli M, Caffarra C, Cavazzoni A, Fumarola C, Galetti M, La Monica S, Ampollini L, Tiseo M, Ardizzoni A, Petronini PR, Alfieri RR (2014) Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Mol Cancer 13:143
31. Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347–356
32. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, EMILIA Study Group (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791
33. Gupta M, Lorusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, Joshi A, Girish S (2012) Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol 52:691–703